At Hikma, our R&D teams are dedicated to delivering high-quality medicines, that reach millions of patients across North America, Europe, and the MENA region. Three key locations power our global network. Ensuring rapid product development and market introduction. We operate three technology platforms; Injectables, Respiratory, Nasal Semi-Solids and Liquids and Oral Solids.
They are supported by global R&D operations including project management, device development, extractables and leachables and nitrosamine laboratory services and Regulatory Affairs. Our API manufacturing facility and independent clinical contract research organisation (IPRC) also support our development teams.
Every R&D programme brings together leading formulation and analytical researchers clinical and non-clinical experts and project managers for outstanding delivery. Our integrated approach connects R&D with product selection intellectual property and operations, driving faster, smarter development.
Our key R&D Injectables expertise is located in Zagreb, Croatia and in Jordan. Our cross-functional teams develop generic and differentiated injectable products. They are supported by dedicated teens to ensure rapid manufacturing introduction.
We deliver diluted and stable products that are ready to be administered the moment patients need them and we continue to advance our expertise to become the leader in complex injectable development.
In our respiratory nasal semi-solids and liquids are R&D hub in Columbus, we develop a range of complex combination products. Our teams are highly skilled in complex state-of-the-art formulation, analytical techniques and clinical research. Automation is embedded in our development process, which increases speed and drives better quality.
R&D for oral solids is located in Jordan and Columbus. Our teams work closely together to develop formulations across multiple therapeutic areas including oncology for all our markets. We use advanced technology and keep building on our oral solids expertise to develop the medicines that patients need.
Our Regulatory Affairs teams collaborate with regulatory agencies to secure product approvals that support our growth, expand up portfolio, and enhance our manufacturing capabilities.
Across all three of our platforms, we collaborate with partners so that we can harness new technologies and bring more complex products to market faster. Ultimately, everything we do is driven by our commitment to Quality. Our rigorous processes ensure regulatory compliance delivering medicines that patients and healthcare providers trust. Our R&D teams around the world are dedicated to achieving this goal. Together, we aim to put better health within reach, every day.
Driving high-value pipeline delivery
$151m invested in R&D in 2025
4.5% of Group core revenue, with an aspiration to reach 5–6% of revenue going forward
3 global R&D hubs
Columbus (Ohio, US), Zagreb (Croatia) and Amman (Jordan)
3 core technology platforms
Injectables; Respiratory, Nasal, Semi-Solids and Liquids; and Solid Orals
84 products launched and 99 approvals received
across our markets in 2025
139 regulatory filings submitted
in 2025 to keep the pipeline moving
300+ products in the pipeline
supporting a portfolio of 825+ products
Hikma is committed to building a differentiated pipeline of complex products. Under a newly unified global R&D organisation, we have consolidated research capabilities into a single Group structure with three hubs. This reorganisation optimises resources, strengthens capabilities, standardises product selection across technical platforms, and accelerates time-to-market, supporting strategic growth priorities.
"Product selection is not a one-time exercise but a continuous, dynamic process where we constantly reprioritise our pipeline based on value creation and the competitive landscape. This requires an agile, engaged team that responds to market changes and emerging opportunities."
Our three technology platforms
Injectables
Led from Zagreb, Croatia, with additional expertise in Jordan, our injectables R&D develops generic and differentiated injectable medicines. Cross-functional teams span formulation, analytical development, medical science and new product transfer, with dedicated support for rapid manufacturing introduction. Our focus is advancing our ambition to lead in complex injectable development.
Respiratory, Nasal, Semi-Solids and Liquids (RNSSL)
Based at our Columbus, Ohio hub, this platform develops complex combination products, including nasal sprays and inhalers. Teams combine state-of-the-art formulation science, advanced analytical techniques and clinical research, with automation embedded throughout to increase speed and quality. Capabilities span formulation, analytical development, clinical and product transfer.
Solid Orals
Developed across our Jordan and Columbus hubs, our solid orals R&D covers multiple therapeutic areas, including oncology, for all our markets. Teams work closely across sites, applying advanced technology to build on our oral solids expertise. Capabilities span formulation, analytical development, clinical and product transfer.
Our three platforms are underpinned by shared global functions that drive consistency, efficiency and harmonised tools across the organisation:
Operations and Regulatory Affairs
R&D Operations — project management, device development, extractables and leachables, and nitrosamine laboratory services.
Regulatory Affairs — our teams collaborate with regulatory agencies including the US FDA, the EMA and MENA health authorities to secure approvals that expand our portfolio and enhance our manufacturing capabilities.
Supporting infrastructure — an API manufacturing facility and an independent clinical contract research organisation (IPRC), which conducts bio-equivalency studies, support our development teams.
Quality at the heart of everything we do
Everything our R&D teams do is anchored in quality. Rigorous processes ensure regulatory compliance and deliver medicines that patients and healthcare providers trust. Our marketed products comply with Current Good Manufacturing Practices (cGMPs), and our quality systems operate in full compliance with the requirements of regulatory agencies across our markets
